XPHState Street SPDR S&P Pharmaceuticals ETF

Grow my money20y track recordRanked #516 of 2,998 in this goal

Tracks the total return performance of the S&P Pharmaceuticals Select Industry Index.

By State Street Investment Management · Launched 2006

Annual Cost

0.35%

#1,651 of 5,861 · low cost

Fund Size

$428M

#1,723 of 5,861 · large

Return (1Y)Goal

+62.9%

Track Record

20 years

#319 of 5,861 · established

Performance

Total-return NAV · USD

Growth of $10,000

$15,175+51.8%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Large

Strategy

Index tracking

Sector

Health care

Focus

Pharmaceuticals

Index tracked

S&P Pharmaceuticals Select Industry Index

What it actually holds

By weight

Concentration

Top 10 holdings = 26.9% of fund✓ well diversified

State Street Global Advisors

7.9%

Enliven Therapeutics Inc

2.4%

Corcept Therapeutics Inc

2.3%

Terns Pharmaceuticals Inc

2.2%

Perrigo Co PLC

2.1%

Axsome Therapeutics Inc

2.0%

Innoviva Inc

2.0%

Merck & Co Inc

2.0%

Pfizer Inc

2.0%

Royalty Pharma PLC

2.0%

Asset allocation

Stocks

99.9%

Cash

0.1%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

22.7%High

Year-on-year price swings

Max drawdown

-36.0%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.75Decent risk-adjusted returns

Sortino (3Y)

1.09Good downside protection

Listing

Exchange: NYSE Arca

Full fund details

Objective: Tracks the total return performance of the S&P Pharmaceuticals Select Industry Index.
Strategy: Invests primarily in securities comprising the S&P Pharmaceuticals Select Industry Index, employing a sampling strategy to hold a portfolio with similar risk and return characteristics. Focuses on U.S. pharmaceuticals with a float-adjusted market capitalization of at least $500 million.
Inception date: June 19, 2006
Fund family: State Street Investment Management